Gautam Jayram, MD, on key bladder cancer agents to keep an eye on

In this video, Guatam Jayram, MD, highlights key agents coming down the pike in bladder cancer. Jayram presented the session “Five things urologists need to know now about bladder and kidney cancer in 2025,” at the 2024 LUGPA Annual Meeting in Chicago, Illinois. Jayram is a urologic oncologist and director of the Advanced Therapeutics Center at Urology Associates of Nashville in Tennessee.

Video Transcript:

There's a lot of trial activity going on with immunotherapy. Specifically with immunotherapy, we have BCG combination trials: BCG plus sasanlimab, BCG plus durvalumab, with a couple trials that are going to read out in the next 12 months. That's going to be really exciting to see if the BCG-naïve population can benefit from combination treatment, and who would benefit the most.

Then the other side of it are some of these other agents. So, cretostimogene [grenadenorepvec] has a really robust trial platform, and that's intravesical gene therapy as well. That has really good data and has a lot of interesting applications, I think, in patients with both intermediate-risk disease and BCG-unresponsive disease in patients with carcinoma in situ. I think that those trials are continuing to improve as we gain more information.

Then you have other players that are in a little bit earlier stages: Protara with lyophilized strep pyogenes, which is an intravesical agent. You have enGene, which is a non-viral vector, intravesical agent that has a lot of promise and could be really easy to give for a community center. Those studies are still accruing; that data is still being accumulated. But there's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us.

This transcript was AI generated and edited by human editors for clarity.